Human Papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2017


  • Products Id :- GMDHC9206IDB
  • |
  • Pages: 229
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Human Papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 5, 41 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 3 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Human Papillomavirus (HPV) Associated Cancer-Overview 9

Human Papillomavirus (HPV) Associated Cancer-Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Human Papillomavirus (HPV) Associated Cancer-Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Human Papillomavirus (HPV) Associated Cancer-Companies Involved in Therapeutics Development 29

Abion Inc 29

Admedus Ltd 29

Advaxis Inc 30

Antigen Express Inc 30

Atara Biotherapeutics Inc 31

BioNTech AG 31

Cancer Research Technology Ltd 32

Cell Medica Ltd 32

Etubics Corp 33

EyeGene Inc 33

Formune SL 34

Genexine Inc 34

Hookipa Biotech AG 35

iBio Inc 35

Immunovaccine Inc 36

Inovio Pharmaceuticals Inc 36

ISA Pharmaceuticals BV 37

Johnson & Johnson 37

Juno Therapeutics Inc 38

Karyopharm Therapeutics Inc 38

Kite Pharma Inc 39

Lion Biotechnologies Inc 39

MedImmune LLC 40

Millennium Pharmaceuticals Inc 40

NeoImmuneTech Inc 41

Onconova Therapeutics Inc 41

Oryx GmbH & Co KG 42

PDS Biotechnology Corp 42

Peregrine Pharmaceuticals Inc 43

Profectus BioSciences Inc 43

Rottapharm Biotech Srl 44

Selecta Biosciences Inc 44

Shantha Biotechnics Ltd 45

Shuttle Pharmaceuticals LLC 45

Sirnaomics Inc 46

Solon Eiendom ASA 46

Theravectys SA 47

THEVAX Genetics Vaccine USA Inc 47

Tomegavax Inc 48

Transgene SA 48

UbiVac LLC 49

Vaccibody AS 49

Vault Pharma Inc 50

Virometix AG 50

VLPbio 51

Human Papillomavirus (HPV) Associated Cancer-Drug Profiles 52

ABI-1968-Drug Profile 52

ABN-301-Drug Profile 53

AEH-10p-Drug Profile 54

alisertib-Drug Profile 55

Antibodies to Inhibit E6 for HPV Associated Cancer-Drug Profile 61

Antibodies to Inhibit E7 for HPV Associated Cancer-Drug Profile 62

ATA-368-Drug Profile 63

AVA-1001-Drug Profile 64

axalimogene filolisbac-Drug Profile 65

bavituximab-Drug Profile 83

BVAC-C-Drug Profile 101

Cellular Immunotherapy for HPV Associated Cancers-Drug Profile 102

Cellular Immunotherapy for HPV Associated Cervical Cancer-Drug Profile 103

Cellular Immunotherapy to Target HPV E6 and E7 Protein for Oncology-Drug Profile 104

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer-Drug Profile 105

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer-Drug Profile 107

CerviVax-Drug Profile 109

CMD-004-Drug Profile 110

CUE-101-Drug Profile 111

CUE-201-Drug Profile 112

DNA Vaccine to Target E7 for HPV Associated Cancers-Drug Profile 113

DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia-Drug Profile 114

DPV-001-Drug Profile 115

DPV-003-Drug Profile 117

DPXE-7-Drug Profile 118

EDA-HPVE7-Drug Profile 120

EG-HPV-Drug Profile 121

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer-Drug Profile 122

ETBX-041-Drug Profile 123

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia-Drug Profile 124

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer-Drug Profile 125

GX-188E-Drug Profile 126

HB-201-Drug Profile 128

HPViNT-Drug Profile 129

human papillomavirus (7-valent) vaccine-Drug Profile 130

human papillomavirus [Serotype 16] vaccine-Drug Profile 131

human papillomavirus [serotypes 16] vaccine-Drug Profile 132

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine biosimilar-Drug Profile 133

human papillomavirus vaccine-Drug Profile 134

human papillomavirus vaccine-Drug Profile 136

human papillomavirus vaccine-Drug Profile 137

INO-3106-Drug Profile 138

INO-3112-Drug Profile 139

ISA-101-Drug Profile 142

ISA-201-Drug Profile 146

KITE-439-Drug Profile 147

LN-145-Drug Profile 149

Monoclonal Antibody Conjugate to Target CD40 for HPV Associated Cervical, Head And Neck Cancer-Drug Profile 151

Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer-Drug Profile 152

Monoclonal Antibody to Target E6 and E7 Proteins for Oncology-Drug Profile 153

NIT-02-Drug Profile 154

NP-001-Drug Profile 155

NSC-721689-Drug Profile 156

Oncolytic Virus to Target E6/E7 for HPV Associated Head and Neck Cancer-Drug Profile 157

PDS-0101-Drug Profile 158

PVX-01-Drug Profile 160

Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer-Drug Profile 161

rigosertib sodium-Drug Profile 162

sdCMV-002-Drug Profile 175

SEL-701-Drug Profile 176

Small Molecules for Solid Tumors and HPV Associated Cancer-Drug Profile 177

Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer-Drug Profile 178

SP-259-Drug Profile 179

STP-900-Drug Profile 180

Subunit Vaccine for HPV Associated Cervical Cancer-Drug Profile 181

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer-Drug Profile 182

TA-CIN-Drug Profile 183

TG-4001-Drug Profile 185

Tricurin-Drug Profile 187

TVGV-1-Drug Profile 188

TVGV-2-Drug Profile 189

Vacc-HPV-Drug Profile 190

Vaccine for HIV and HPV Associated Cancer-Drug Profile 191

Vaccine for HPV Associated Cancer-Drug Profile 192

Vaccine for HPV Associated Cancers-Drug Profile 193

Vaccine for HPV Associated Cervical Cancer-Drug Profile 194

Vaccine for HPV Associated Cervical Cancer-Drug Profile 195

Vaccine for HPV Associated Non-Melanoma Skin Cancer-Drug Profile 196

Vaccine for Human Papillomavirus Associated Cervical Cancer-Drug Profile 197

VB-1016-Drug Profile 198

verdinexor-Drug Profile 201

VGX-3100-Drug Profile 202

Vicoryx-Drug Profile 205

VMT-2-Drug Profile 206

VPI-241-Drug Profile 207

Vvax-001-Drug Profile 208

Human Papillomavirus (HPV) Associated Cancer-Dormant Projects 209

Human Papillomavirus (HPV) Associated Cancer-Discontinued Products 211

Human Papillomavirus (HPV) Associated Cancer-Product Development Milestones 212

Featured News & Press Releases 212

Appendix 222

Methodology 222

Coverage 222

Secondary Research 222

Primary Research 222

Expert Panel Validation 222

Contact Us 222

Disclaimer 223

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Abion Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Admedus Ltd, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Advaxis Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Antigen Express Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Atara Biotherapeutics Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by BioNTech AG, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Cancer Research Technology Ltd, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Cell Medica Ltd, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Etubics Corp, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by EyeGene Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Formune SL, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Genexine Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Hookipa Biotech AG, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by iBio Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Immunovaccine Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by ISA Pharmaceuticals BV, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Johnson & Johnson, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Juno Therapeutics Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Kite Pharma Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Lion Biotechnologies Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by MedImmune LLC, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by NeoImmuneTech Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Onconova Therapeutics Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Oryx GmbH & Co KG, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by PDS Biotechnology Corp, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Profectus BioSciences Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Rottapharm Biotech Srl, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Selecta Biosciences Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Shantha Biotechnics Ltd, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Sirnaomics Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Solon Eiendom ASA, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Theravectys SA, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Tomegavax Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Transgene SA, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by UbiVac LLC, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Vaccibody AS, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Vault Pharma Inc, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by Virometix AG, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Pipeline by VLPbio, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Dormant Projects, H1 2017

Human Papillomavirus (HPV) Associated Cancer-Dormant Projects, H1 2017 (Contd..1), H1 2017

Human Papillomavirus (HPV) Associated Cancer-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abion Inc, Admedus Ltd, Advaxis Inc, Antigen Express Inc, Atara Biotherapeutics Inc, BioNTech AG, Cancer Research Technology Ltd, Cell Medica Ltd, Etubics Corp, EyeGene Inc, Formune SL, Genexine Inc, Hookipa Biotech AG, iBio Inc, Immunovaccine Inc, Inovio Pharmaceuticals Inc, ISA Pharmaceuticals BV, Johnson & Johnson, Juno Therapeutics Inc, Karyopharm Therapeutics Inc, Kite Pharma Inc, Lion Biotechnologies Inc, MedImmune LLC, Millennium Pharmaceuticals Inc, NeoImmuneTech Inc, Onconova Therapeutics Inc, Oryx GmbH & Co KG, PDS Biotechnology Corp, Peregrine Pharmaceuticals Inc, Profectus BioSciences Inc, Rottapharm Biotech Srl, Selecta Biosciences Inc, Shantha Biotechnics Ltd, Shuttle Pharmaceuticals LLC, Sirnaomics Inc, Solon Eiendom ASA, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Tomegavax Inc, Transgene SA, UbiVac LLC, Vaccibody AS, Vault Pharma Inc, Virometix AG, VLPbio

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com